17 Kasım 2026, Salı · 16:21 Piyasalar Açık
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Kilo Kaybı İlaç Denemesinden Sonra Viking Therapeutics (VKTX) Roketleri % 35,7 — Satış Noktası Nedir?

Viking Therapeutics (VKTX) Rockets 35.7% After Weight Loss Drug Trial — What’s The Selling Point?

Angelica Ballesteros

Wed, September 23, 2026 at 1:37 AM GMT+3 3 min read

Viking Therapeutics Inc. (NASDAQ:VKTX) soared by a whopping 35.67 percent on Tuesday to close at $40.85 apiece—just $2 shy of its 52-week high—after reporting stellar results from its weight loss drug candidate, VK2735.

After 21 weeks of clinical trial, the company said that enrolled patients who took VK2735 successfully lost 16 to 19 percent of their body weight, versus none in the placebo group.

Participants were randomized to receive weekly doses of VK2735 or placebo for 21 weeks. Beginning in Week 3, VK2735 doses were escalated every two weeks until final doses of 15 mg, 17.5 mg, 20 mg, or 22.5 mg were reached.

During the 12-week maintenance period, only minimal side effects were observed, such as nausea, vomiting, diarrhea, constipation, and stomach discomfort.

For illustration purposes only. Photo by Cherries on Shutterstock

The Selling Point

The weight-loss percentage figures appeared to be just secondary.

For Viking Therapeutics Inc. (NASDAQ:VKTX), the selling point of VK2735 is the ability for patients to maintain their weight loss without having to inject themselves regularly.

Instead of every week, the company is testing whether people can take injections every two weeks or once a month.

"The results of our innovative maintenance dosing study continue to demonstrate the significance of VK2735's unique and differentiated half-life and PK profile, which appear to enable an effective new approach to achieving and maintaining the weight loss goals of patients living with obesity," Viking Therapeutics Inc. (NASDAQ:VKTX) CEO Brian Lian said.

Analyst Remains Neutral

Despite the solid data, investment firm Goldman Sachs remained neutral about Viking Therapeutics Inc. (NASDAQ:VKTX), saying that the results were encouraging but were anticipated given the study design with multiple dosing options.

Goldman Sachs believed that a longer follow-up period is required to assess the durability of weight loss maintenance, especially for monthly doses.

The investment firm also reiterated its $38 price target for the stock, or a 7 percent discount from its latest closing price.

Hedge Funds More Bullish

Institutional investors, however, were bullish about their long-term growth prospects for Viking Therapeutics Inc. (NASDAQ:VKTX) even prior to the results.

Data from Insider Monkey showed that in the second quarter of the year, 47 hedge funds held positions in the stock, up from 44 in the first quarter of the year.

More notably, their combined holdings increased by 25 percent to $551 million from $441 million quarter-on-quarter.

As these predate the clinical trial data, investors will then have to watch out for the updated third-quarter hedge fund holdings to determine whether the results have helped encourage further buying in the stock.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.

Kaynak: Yahoo Finance
İlgili Haberler
Global "Breaking Bad" dizisinin yıldızı Dean Norris, boşanma sürecindeyken 4,5 hektarlık Kaliforniya'daki mülkünü 3,2 milyon dolara satıyor MarketWatch Top · 3 saat önce Global Nvidia'dan Apple'a kadar ABD'li şirketler artan bir Çin ikilemiyle karşı karşıya CNBC Finance · 4 saat önce Global Berkshire Hathaway raised its stake in Delta in the third quarter. It also trimmed a key bank holding CNBC Finance · 14 saat önce Global JPMorgan Chase says temporary software bug is affecting consumer banking CNBC Finance · 15 saat önce Global Sanayi üretimi, perakende satışlar ve yatırımların tahminlerin altında kalmasıyla Çin'deki yavaşlama Ekim ayında daha da derinleşti CNBC Finance · 1 gün önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.